Leap Therapeutics (NASDAQ:LPTX) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Leap Therapeutics (NASDAQ:LPTX) in a research note released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright decreased their target price on shares of Leap Therapeutics from $7.00 to $5.50 and set a buy rating on the stock in a research report on Tuesday, May 14th. Robert W. Baird decreased their target price on shares of Leap Therapeutics from $11.00 to $9.00 and set an outperform rating on the stock in a research report on Tuesday, March 19th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Leap Therapeutics has a consensus rating of Buy and a consensus price target of $10.40.

Leap Therapeutics Trading Up 10.7 %

Shares of NASDAQ LPTX opened at $1.96 on Friday. Leap Therapeutics has a 12 month low of $1.24 and a 12 month high of $5.00. The company has a 50-day simple moving average of $2.53 and a 200-day simple moving average of $2.87.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Monday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.06. As a group, analysts expect that Leap Therapeutics will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Leap Therapeutics by 111.7% during the first quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after buying an additional 457,904 shares in the last quarter. 683 Capital Management LLC lifted its position in Leap Therapeutics by 60.7% during the third quarter. 683 Capital Management LLC now owns 490,000 shares of the company’s stock valued at $676,000 after buying an additional 185,001 shares in the last quarter. Acuta Capital Partners LLC acquired a new position in Leap Therapeutics during the third quarter valued at approximately $489,000. Acadian Asset Management LLC lifted its position in shares of Leap Therapeutics by 349.3% during the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock worth $750,000 after purchasing an additional 219,563 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC lifted its position in shares of Leap Therapeutics by 8.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 233,018 shares of the company’s stock worth $620,000 after purchasing an additional 18,408 shares in the last quarter. 30.46% of the stock is owned by institutional investors and hedge funds.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.